SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-012643
Filing Date
2020-08-13
Accepted
2020-08-13 17:13:37
Documents
48
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rgls-20200630.htm   iXBRL 10-Q 1665605
2 EX-31.1 ex-311x20200630.htm EX-31.1 12283
3 EX-31.2 ex-312x20200630.htm EX-31.2 12260
4 EX-32.1 ex-321x20200630.htm EX-32.1 13514
  Complete submission text file 0001628280-20-012643.txt   6146219

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgls-20200630.xsd EX-101.SCH 35081
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgls-20200630_cal.xml EX-101.CAL 56193
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgls-20200630_def.xml EX-101.DEF 219636
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgls-20200630_lab.xml EX-101.LAB 504340
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgls-20200630_pre.xml EX-101.PRE 310441
10 EXTRACTED XBRL INSTANCE DOCUMENT rgls-20200630_htm.xml XML 929582
Mailing Address 10628 SCIENCE CENTER DRIVE SUITE 225 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE SUITE 225 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35670 | Film No.: 201100223
SIC: 2834 Pharmaceutical Preparations